BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...trials in Chinese populations for therapies approved elsewhere, and on the other, developing a de novo...
BioCentury | Jan 21, 2021
Deals

Jan. 20 Quick Takes: Beam adds $260M; plus Lilly-Merus, Thermo Fisher-Mesa, Verve, Aclaris, ViGeneron-Daiichi Sankyo

...Capital. Also participating were Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Novo...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...Copenhagen Herlev Hospital’s Center for Cancer Immune Therapy in 2015 with a seed investment from Novo...
...from “cold” to “hot.”“The key differentiator here is that this is a vaccination approach,” said Novo...
...Generic), Opdivo (Other) IO102 IO103 Keytruda, pembrolizumab (MK-3475, lambrolizumab) IO Biotech ApS HBM Healthcare Investments University of Copenhagen Novo Seeds Bristol Myers Squibb Co. Novo...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

...from sequence,” said Jonathan Drachman, CEO of de novo protein...
...could benefit from the advance is de novo...
...and improve predictions of the structures de novo...
BioCentury | Jan 8, 2021
Finance

More strategics pile into Dutch early-stage investor BGV’s largest-ever fund

...€140 million fourth fund gains new strategic backers Lilly, Novo Ventures By Jeff Cranmer, Executive Editor...
...topped off its largest-ever fund with a further €35 million and new strategic backers Lilly and Novo...
...disclosed: an €18.5 million series B round in Citryll B.V. in July.Eli Lilly and Co. (NYSE:LLY) and Novo...
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...Co. (NYSE:BMY) and Novo Nordisk A/S (CSE:NOVO; NYSE:NOVO...
...also exploring the NK cell checkpoint space. Novo...
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...Phase II testing. New investors Sanofi Ventures, Wellington Partners, Adjuvant Capital and Industrifonden joined prior backers Novo...
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...amyloid, with the latest coming Wednesday from Novo...
...well-understood.Novo takes semaglutide into neuroNovo Nordisk A/S (CSE:NOVO...
...and enrolled a different patient population than Novo...
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...Seeds is funding Hemab ApS, which emerged with an exclusive license from Novo Nordisk A/S (CSE:NOVO...
...DuoBody platform from Genmab A/S (CSE:GMAB; NASDAQ:GMAB). Novo Seeds partner Jørgen Petersen was appointed Hemab’s chairman; Camilla Hansen, Novo...
...Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida Ventures RA Capital Management Invus Acuta Capital Partners SVB Leerink Arch Venture Partners Temasek Lightstone Ventures UCB Ventures GV Novo Holdings Novo...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...be completed next quarter, with a commercial launch in 2H21.Novo Nordisk Foundation spins out incubatorThe Novo...
Items per page:
1 - 10 of 2801
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...trials in Chinese populations for therapies approved elsewhere, and on the other, developing a de novo...
BioCentury | Jan 21, 2021
Deals

Jan. 20 Quick Takes: Beam adds $260M; plus Lilly-Merus, Thermo Fisher-Mesa, Verve, Aclaris, ViGeneron-Daiichi Sankyo

...Capital. Also participating were Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Novo...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...Copenhagen Herlev Hospital’s Center for Cancer Immune Therapy in 2015 with a seed investment from Novo...
...from “cold” to “hot.”“The key differentiator here is that this is a vaccination approach,” said Novo...
...Generic), Opdivo (Other) IO102 IO103 Keytruda, pembrolizumab (MK-3475, lambrolizumab) IO Biotech ApS HBM Healthcare Investments University of Copenhagen Novo Seeds Bristol Myers Squibb Co. Novo...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

...from sequence,” said Jonathan Drachman, CEO of de novo protein...
...could benefit from the advance is de novo...
...and improve predictions of the structures de novo...
BioCentury | Jan 8, 2021
Finance

More strategics pile into Dutch early-stage investor BGV’s largest-ever fund

...€140 million fourth fund gains new strategic backers Lilly, Novo Ventures By Jeff Cranmer, Executive Editor...
...topped off its largest-ever fund with a further €35 million and new strategic backers Lilly and Novo...
...disclosed: an €18.5 million series B round in Citryll B.V. in July.Eli Lilly and Co. (NYSE:LLY) and Novo...
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...Co. (NYSE:BMY) and Novo Nordisk A/S (CSE:NOVO; NYSE:NOVO...
...also exploring the NK cell checkpoint space. Novo...
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...Phase II testing. New investors Sanofi Ventures, Wellington Partners, Adjuvant Capital and Industrifonden joined prior backers Novo...
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...amyloid, with the latest coming Wednesday from Novo...
...well-understood.Novo takes semaglutide into neuroNovo Nordisk A/S (CSE:NOVO...
...and enrolled a different patient population than Novo...
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...Seeds is funding Hemab ApS, which emerged with an exclusive license from Novo Nordisk A/S (CSE:NOVO...
...DuoBody platform from Genmab A/S (CSE:GMAB; NASDAQ:GMAB). Novo Seeds partner Jørgen Petersen was appointed Hemab’s chairman; Camilla Hansen, Novo...
...Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida Ventures RA Capital Management Invus Acuta Capital Partners SVB Leerink Arch Venture Partners Temasek Lightstone Ventures UCB Ventures GV Novo Holdings Novo...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...be completed next quarter, with a commercial launch in 2H21.Novo Nordisk Foundation spins out incubatorThe Novo...
Items per page:
1 - 10 of 2801